ROS1 and neoplasm: A phase I trial is assessing the pan-TRK, ROS1 and ALK inhibitor entrectinib in paediatric patients with relapsed or refractory solid and Central Nervous System (CNS) tumours with and without TRK, ROS1 and ALK fusions (NCT02650401).